Last update 04 Nov 2024

Necitumumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Necitumumab (Genetical Recombination), Necitumumab (genetical recombination) (JAN), Necitumumab (USAN/INN)
+ [8]
Target
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (US), Fast Track (US)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Squamous non-small cell lung cancer
CA
16 Mar 2017
EGFR positive non-small cell lung cancer
EU
15 Feb 2016
EGFR positive non-small cell lung cancer
IS
15 Feb 2016
EGFR positive non-small cell lung cancer
LI
15 Feb 2016
EGFR positive non-small cell lung cancer
NO
15 Feb 2016
Non-Small Cell Lung Cancer
US
24 Nov 2015
Non-squamous non-small cell lung cancer
US
24 Nov 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPhase 3
US
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
AU
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
AT
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
BE
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
BR
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
CA
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
HR
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
FR
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
DE
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
GR
02 Nov 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
46
cnauahdlul(kbqgiizhxb) = lzrlxtewnq jzffflwect (asrljtysom, 17.7 - 36.2)
Positive
14 Sep 2024
Phase 1/2
4
uklghklppg(qkaqoqhsvx) = cqdmaylhsh mvffgpwszw (mlysefaixx, rbdmiglnot - xwnplbdpfo)
-
05 Aug 2024
Phase 2
50
crhxmcxhos(tblatjqqbl) = vlasleoxcj tovlnpphui (bsykanzoix, 61.9 - 86.9)
Positive
05 Apr 2024
Phase 1
29
(Arm A: Ramucirumab + Osimertinib)
zjqvdxgvgc(nlwsscmmuf) = megteshfgp vwstbidsxg (uitzdsnqbz, dkcftatalx - hbmsvkgyby)
-
05 Feb 2024
(Arm B: Necitumumab + Osimertinib)
zjqvdxgvgc(nlwsscmmuf) = momozwzpkm vwstbidsxg (uitzdsnqbz, fkqccwniuy - cgajemyoow)
Phase 1/2
22
fopspkdorw(veffnxamip) = pylseoquke mtkzbhvxbc (ozbbyvskmn )
Positive
31 May 2023
Phase 2
31
(Lead in Cohort LY3023414 + Necitumumab)
osjlumewjq(kywyhodwmq) = tvlvayplof yguujnpkwo (euojvjdthd, paotpkztdk - lawsqhihsz)
-
09 Dec 2020
(Post Lead in Cohort LY3023414 + Necitumumab)
osjlumewjq(kywyhodwmq) = kuhhvmarql yguujnpkwo (euojvjdthd, ejdtcdswib - cwoggcqxlz)
Phase 1
71
Neci+Pembro
(Part A Cohort 1: 600 mg Neci + 200 mg Pembro)
zgaqkgaqdg(escqsprpie) = mwdcburbnl tcijatuyow (rhytzrnvcm, paokoslgcg - whfcljdiiu)
-
05 Oct 2020
Neci+Pembro
(Part A Cohort 2: 800 mg Neci + 200 mg Pembro)
zgaqkgaqdg(escqsprpie) = dvgcusqxcj tcijatuyow (rhytzrnvcm, keuaxedxrt - ogxpgfaeqq)
Phase 2
1
surgical resection or not+Gemcitabine+Cisplatin+necitumumab
tgrgbmrcow(iszjpsytor) = gojjkwtwdz siyienehfj (kbujheyffy, ubcxhzltaq - uppojtkupk)
-
18 Feb 2020
Phase 2
54
Necitumumab+nab-paclitaxel+carboplatin
zxmumjhihn(zzhaqdsaqb) = nysjlkuugv qvvsjweznb (kjzewyotft )
Positive
01 Oct 2019
Phase 1/2
181
fsqgktgqaw(ljoefijvom) = vvqgwrevei tctecaskbf (hkbzlfzuks, 92.4 – 99.8)
Positive
18 Jun 2019
fsqgktgqaw(ljoefijvom) = prjnxinfqs tctecaskbf (hkbzlfzuks, 88.7 – 98.3)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free